Pub. Date : 2016 Mar 7
PMID : 26796063
27 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. | CUDC-907 | ATP binding cassette subfamily A member 4 | Homo sapiens |
| 2 | Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 3 | Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 4 | Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. | CUDC-907 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | Homo sapiens |
| 5 | CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 6 | CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 7 | CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). | CUDC-907 | phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta | Homo sapiens |
| 8 | Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 9 | Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth. | CUDC-907 | zinc fingers and homeoboxes 2 | Homo sapiens |
| 10 | Treatment with CUDC-907 led to sustained inhibition of HDAC and PI3K activity, inhibition of RAF-MEK-MAPK signaling pathway, and inhibition of cancer cell growth. | CUDC-907 | mitogen-activated protein kinase kinase 7 | Homo sapiens |
| 11 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 12 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 13 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 14 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 15 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 16 | In this study, we reveal that ABCG2 reduces the intracellular accumulation of CUDC-907 and confers significant resistance to CUDC-907, which leads to reduced activity of CUDC-907 to inhibit HDAC and PI3K in human cancer cells. | CUDC-907 | histone deacetylase 9 | Homo sapiens |
| 17 | Moreover, although CUDC-907 affects the transport function of ABCG2, it was not potent enough to reverse drug resistance mediated by ABCG2 or affect the expression level of ABCG2 in human cancer cells. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 18 | Taken together, our findings indicate that ABCG2-mediated CUDC-907 resistance can have serious clinical implications and should be further investigated. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 19 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 20 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 21 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 22 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 23 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 24 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 25 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 26 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |
| 27 | More importantly, we demonstrate that the activity of CUDC-907 in ABCG2-overexpressing cancer cells can be restored by inhibiting the function of ABCG2, which provides support for the rationale of combining CUDC-907 with modulators of ABCG2 to improve the pharmacokinetics and efficacy of CUDC-907 in future treatment trials. | CUDC-907 | ATP binding cassette subfamily G member 2 (Junior blood group) | Homo sapiens |